Portal de investigación
AGILE: A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Ivosidenib in Combination with Azacitidine in Adult Patients with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Recher, Christian
- Doronin, Vadim
- Calado, Rodrigo T.
- Jang, Jun Ho
- Miyazaki, Yasushi
- Wang, Jianxiang
- Gianolio, Diego A.
- Daigle, Scott R.
- Winkler, Thomas
- Zhang, Vickie
- Paschka, Peter
Grupos
Abstract
Abstract no disponible
Datos de la publicación
- ISSN/ISSNe:
- 0006-4971, 1528-0020
- Tipo:
- Meeting Abstract
- Páginas:
- -
- Factor de Impacto:
- 5,416 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
BLOOD ELSEVIER
Citas Recibidas en Web of Science: 8
Documentos
- No hay documentos
Filiaciones
Filiaciones no disponibles
Campos de Estudio
Cita
Montesinos,P,Recher,C,Doronin,V,Calado,RT,Jang,JH,Miyazaki,Y,Wang,J et al. AGILE: A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Ivosidenib in Combination with Azacitidine in Adult Patients with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation. 61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH). 2019. Orlando-FL. RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS:ELSEVIER. 2019.